These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32279422)

  • 1. Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis.
    Bossen L; Rebora P; Bernuzzi F; Jepsen P; Gerussi A; Andreone P; Galli A; Terziroli B; Alvaro D; Labbadia G; Aloise C; Baiocchi L; Giannini E; Abenavoli L; Toniutto P; Marra F; Marzioni M; Niro G; Floreani A; Møller HJ; Valsecchi MG; Carbone M; Grønbaek H; Invernizzi P
    Liver Int; 2020 Jun; 40(6):1408-1414. PubMed ID: 32279422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary Cholangitis.
    Fujinaga Y; Namisaki T; Tsuji Y; Suzuki J; Murata K; Takeda S; Takaya H; Inoue T; Noguchi R; Fujimoto Y; Enomoto M; Nishimura N; Kitagawa K; Kaji K; Kawaratani H; Akahane T; Mitoro A; Yoshiji H
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.
    Laursen TL; Wong GL; Kazankov K; Sandahl T; Møller HJ; Hamilton-Dutoit S; George J; Chan HL; Grønbaek H
    J Gastroenterol Hepatol; 2018 Feb; 33(2):484-491. PubMed ID: 28618015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial.
    Kimer N; Gudmann NS; Pedersen JS; Møller S; Nielsen MJ; Leeming DJ; Karsdal MA; Møller HJ; Bendtsen F; Grønbæk H
    PLoS One; 2018; 13(9):e0203200. PubMed ID: 30183743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis.
    Bossen L; Vesterhus M; Hov JR; Färkkilä M; Rosenberg WM; Møller HJ; Boberg KM; Karlsen TH; Grønbæk H
    Clin Transl Gastroenterol; 2021 Mar; 12(3):e00315. PubMed ID: 33646203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study.
    Andersen ES; Rødgaard-Hansen S; Moessner B; Christensen PB; Møller HJ; Weis N
    Eur J Clin Microbiol Infect Dis; 2014 Jan; 33(1):117-22. PubMed ID: 24424890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage markers soluble CD163 and soluble mannose receptor are associated with liver injury in patients with paracetamol overdose.
    Siggaard CB; Kazankov K; Rødgaard-Hansen S; Møller HJ; Donnelly MC; Simpson KJ; Grønbaek H
    Scand J Gastroenterol; 2019 May; 54(5):623-632. PubMed ID: 31067143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).
    Grønbæk H; Rødgaard-Hansen S; Aagaard NK; Arroyo V; Moestrup SK; Garcia E; Solà E; Domenicali M; Piano S; Vilstrup H; Møller HJ;
    J Hepatol; 2016 Apr; 64(4):813-22. PubMed ID: 26639396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monocyte expression and soluble levels of the haemoglobin receptor (CD163/sCD163) and the mannose receptor (MR/sMR) in septic and critically ill non-septic ICU patients.
    Kjærgaard AG; Rødgaard-Hansen S; Dige A; Krog J; Møller HJ; Tønnesen E
    PLoS One; 2014; 9(3):e92331. PubMed ID: 24637679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation.
    Rainer F; Horvath A; Sandahl TD; Leber B; Schmerboeck B; Blesl A; Groselj-Strele A; Stauber RE; Fickert P; Stiegler P; Møller HJ; Grønbaek H; Stadlbauer V
    Aliment Pharmacol Ther; 2018 Mar; 47(5):657-664. PubMed ID: 29266346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between soluble CD163, disease severity, and ursodiol treatment in patients with primary biliary cholangitis.
    Bossen L; Lau TS; Nielsen MB; Nielsen MC; Andersen AH; Ott P; Becker S; Glerup H; Svenningsen L; Eivindson M; Kornerup L; Kjeldsen NB; Neumann A; Møller HJ; Jepsen P; Grønbæk H
    Hepatol Commun; 2023 Apr; 7(4):. PubMed ID: 36972379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): Implications in multiple myeloma.
    Andersen MN; Andersen NF; Rødgaard-Hansen S; Hokland M; Abildgaard N; Møller HJ
    Leuk Res; 2015 Sep; 39(9):971-5. PubMed ID: 26169445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease.
    Kazankov K; Alisi A; Møller HJ; De Vito R; Rittig S; Mahler B; Nobili V; Grønbæk H
    J Pediatr Gastroenterol Nutr; 2018 Nov; 67(5):635-642. PubMed ID: 30074574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C.
    Kazankov K; Barrera F; Møller HJ; Bibby BM; Vilstrup H; George J; Grønbaek H
    Hepatology; 2014 Aug; 60(2):521-30. PubMed ID: 24623375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation.
    Grønbaek H; Møller HJ; Saliba F; Zeuzem S; Albillos A; Ariza X; Graupera I; Solà E; Amoros A; Pavesi M; Bossen L; Jalan R; Gines P; Arroyo V
    J Gastroenterol Hepatol; 2021 Jan; 36(1):240-248. PubMed ID: 32478437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study.
    Björklund J; Laursen TL; Sandahl TD; Møller HJ; Vilstrup H; Ott P; Grønbæk H
    Orphanet J Rare Dis; 2018 Sep; 13(1):169. PubMed ID: 30241550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease.
    Glavind E; Gotthardt DN; Pfeiffenberger J; Sandahl TD; Bashlekova T; Willemoe GL; Hasselby JP; Weiss KH; Møller HJ; Vilstrup H; Lee WM; Schilsky ML; Ott P; Grønbæk H
    Orphanet J Rare Dis; 2020 Jul; 15(1):173. PubMed ID: 32615997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent effects on macrophage biomarkers soluble CD163 and CD206 in axial spondyloarthritis.
    Heftdal LD; Loft AG; Hendricks O; Ashouri Christiansen A; Schiøttz-Christensen B; Arnbak B; Jurik AG; Østgård R; Winding Deleuran B; Møller HJ; Greisen SR
    Scand J Clin Lab Invest; 2018 Oct; 78(6):483-489. PubMed ID: 30176763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The macrophage activation marker sMR as a diagnostic and prognostic marker in patients with acute infectious disease with or without sepsis.
    Marie Relster M; Gaini S; Møller HJ; Johansen IS; Pedersen C
    Scand J Clin Lab Invest; 2018 May; 78(3):180-186. PubMed ID: 29383956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular vesicle-associated soluble CD163 and CD206 in patients with acute and chronic inflammatory liver disease.
    Nielsen MC; Andersen MN; Grønbæk H; Damgaard Sandahl T; Møller HJ
    Scand J Gastroenterol; 2020 May; 55(5):588-596. PubMed ID: 32393080
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.